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Direct aorticBackground: Surgical subclavian (SC) and direct aortic (DA) access are established alternatives to the default
transfemoral route for transcatheter aortic valve implantation (TAVI). We sought to find differences in survival
and procedure-related outcomes after SC- versus DA-TAVI.
Methods:Weperformed an observational cohort analysis of cases prospectively uploaded to theUK TAVI registry.
To ensure the most contemporaneous comparison, the analysis focused on SC and DA procedures performed
from 2013 to 2015.
Results: Between January 2013 and July 2015, 82 (37%) SC and 142 (63%) DA cases were performed that had val-
idated 1-year life status.Multivariable regression analysis showedprocedure durationwas longer for SC cases (SC
193.5± 65.8 vs. DA 138.4± 57.7min; p b .01) but length of hospital staywas shorter (SC 8.6± 9.5 vs. DA 11.9±
10.8 days; p = .03). Acute kidney injury was observed less frequently after SC cases (odds ratio [OR] 0.35, 95%
confidence interval [CI 0.12–0.96]; p= .042) but vascular access site-related complications were more common
(OR 9.75 [3.07–30.93]; p b .01). Procedure-related bleeding (OR 0.54 [0.24–1.25]; p= .15) and in-hospital stroke
rate (SC 3.7% vs. DA 2.1%; p= .67) were similar. There were no significant differences in in-hospital (SC 2.4% vs.
DA 4.9%; p = .49), 30-day (SC 2.4% vs. DA 4.2%; p= .71) or 1-year (SC 14.5% vs. DA 21.9%; p = .344) mortality.ton and Sussex University Hospitals NHS Trust, Eastern Road, Brighton BN2 5BE, UK.
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liability and freedom from bias of the data presented and their discussed interpretation.
68 A. Myat et al. / International Journal of Cardiology 308 (2020) 67–72Conclusions: Surgical subclavian and direct aortic approaches can offer favourable outcomes in appropriate pa-
tients. Neither access modality conferred a survival advantage but there were significant differences in proce-
dural metrics that might influence which approach is selected.
© 2020 Published by Elsevier B.V.1. Introduction
The retrograde transfemoral (TF) route is the established default vas-
cular access for transcatheter aortic valve implantation (TAVI) [1,2]. In
some patients, however, the transfemoral approach is not possible be-
cause of significant atherosclerotic disease and/or unsuitable iliofemoral
anatomy, such as tortuosity or small calibre. Alternatives include the
transapical (TA), direct aortic (DA), subclavian or axillary (SC), carotid
and transcaval access sites. With the miniaturisation of TAVI delivery
systems and the relative invasiveness of surgical thoracotomy in often
multi-morbid patients, TA access is now performed less frequently in
the United Kingdom (UK). Consequently the SC and DA routes have be-
come the predominant alternative surgical approaches, both performed
under general anaesthetic. Either approachmandate a surgical cutdown
- the former to the subclavian artery and the latter via an upper partial
sternotomy or small right anterior thoracotomy. Both were originally
developed for the Medtronic CoreValve (Medtronic, Dublin, Ireland)
due to its longer profile, which made a TA approach problematic. The
DA access can also be used for the Edwards Lifesciences Sapien (Irvine,
CA, USA) valve.
There is a lack of data directly comparing outcomes after SC versus
DA access TAVI. Hence we analysed the UK TAVI national registry to de-
termine whether there was a difference in short- and medium-term
survival and other important procedure-related outcomes between
these two alternative vascular access approaches.
2. Methods
The UK TAVI registry has recorded baseline demographics, proce-
dural characteristics, complications and clinical outcomes for every pa-
tient treated with TAVI since January 2007. It is mandatory to complete
the dataset for every individual undergoing attempted TAVI in the UK.
The data are collated and the process quality controlled by the National
Institute of Cardiovascular Outcomes Research (NICOR) [1,3,4].
The current study is an observational cohort analysis of all proce-
dures prospectively uploaded to the NICOR servers from January 2007
to December 2015. A Heart Team in each centre determined patient el-
igibility for TAVI, selected prosthesis type and corresponding access
route according to size and degree of tortuosity, calcification, and ather-
oma of the aorto-iliofemoral arterial tree. All patients provided written
informed consent at the time of their TAVI procedure as per standard in-
stitutional protocols. We identified all those who had TAVI performed
via the SC versus DA access route and compared them according to pa-
tient and procedural characteristics, clinical outcomes and survival.
Missing data were excluded from the analyses.
DA access has only been used from2013onwards, whereas SC access
was available from 2007. To ensure a more contemporaneous and sta-
tistically more robust comparison of SC versus DA access outcomes,
we focussed our analyses on procedures performed from January 2013
to July 2015. We used multivariable regression to adjust for remaining
confounding.
The primary analysis looked at 30-day and 1-year all-cause
mortality after SC versus DA access TAVI up to July 2015. The sec-
ondary analysis was designed to investigate important process
measures and postoperative complications including: procedure
duration, postoperative length-of-stay (LoS), vascular access site
and related complications, in-hospital permanent pacemaker implan-
tation (PPI), pericardial tamponade, valve embolization, further valveintervention before discharge, stroke, bleeding, aortic valve regurgita-
tion, acute kidney injury (AKI) and requirement for new renal replace-
ment therapy.
2.1. Data cleaning
Registry results are presented to the British Cardiovascular
õIntervention Society (BCIS) annually, ensuring continual validation
and verification of data integrity. All data, inclusive of peri- and
postprocedural complications up to hospital discharge are reported
by each participating TAVI centre in accordance with the definitions
outlined by the national dataset. Range checks to expose extreme
values and assessments of internal consistency are applied when in-
dividual records are uploaded to the central NICOR server. Centres
uploading records with missing, extreme, or inconsistent values are
contacted and asked to ratify records if necessary.
2.2. Mortality tracking
Patients undergoing TAVI in England and Wales (comprising the
vast majority of procedures in the registry), are linked to the Office of
National Statistics by theNational Health Service (NHS) Central Register
via a unique NHSnumber. This provides a robust system for tracking all-
cause mortality. Validated life status data were available for patients up
to July 2015. Thiswasused for survival analyses at 30 days and 1 year for
the current investigation. NICOR has support under section 251 of the
NHS Act 2006. According to NHS research governance arrangements,
formal ethics approval was not required for this study [1,3]. This study
was conducted in accordance with the Declaration of Helsinki and
good clinical practice.
2.3. Statistical analysis
Continuous variables are summarised as mean and standard devia-
tion, or as median and interquartile ranges (IQR) where appropriate.
Unadjusted differences were assessed with the two-sample t-test, or
two-sample Wilcoxon rank-sum test. Categorical variables are pre-
sented as absolute numbers and percentages, and comparison between
groupswas undertaken by the χ2, or Fisher exact tests (the latter for var-
iables with five events or less per group); ordinal categorical variables
were compared using the linear-by-linear association test, taking into
account their ordered nature. A Kaplan-Meier survival curve was pro-
duced to illustrate the percentage survival of all patients undergoing
SC versus DA TAVI from 2013 to 2015 with log-rank test p-values addi-
tionally obtained. Survival was examined as a time-to-event outcome,
using the Cox proportional hazardsmodel. The proportional hazards as-
sumption was assessed using scaled Schoenfeld residuals.
Linear regression models were employed for continuous outcomes
(considering logarithmic transformations to address non-normality is-
sues where necessary), and binary outcomes analysed using logistic re-
gression. In order to adjust for selection bias, candidate covariates
considered for risk-adjustment were age at operation, sex, body mass
index (BMI), Canadian Study of Health and Aging (CSHA) clinical frailty
score, diabetes, history of pulmonary disease, previous myocardial in-
farction (MI), previous percutaneous coronary intervention (PCI), previ-
ous cardiac surgery, elective procedure (or not), extensive calcification
of ascending aorta, aortic balloon valvuloplasty, and year of operation;
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literature.
Multivariable regression analysiswas undertaken to examine the as-
sociation of access routewith the co-primary outcomes, adjusted for pa-
tient characteristics. Multivariable models were further used for all
other continuous outcomes, and binary outcomes with a sufficient
number of events to allow for modelling. Note that procedure-related
bleeding and AKI were modelled as binary variables if these occurred,
but not their gravity. Relevant predictors for each outcome of interest
were identified by first performing univariable regression analyses;
those variables found significant (i.e. with 2-sided p-value b.05) were
subsequently assessed simultaneously in multivariable models. Addi-
tional sensitivity analysis to assess the impact of selection bias was un-
dertaken. Propensity score matching was performed but the results
obtained were similar to those in the adjusted regression analysis so
were therefore omitted. A 2-sided p-value b.05 was considered signifi-
cant for all statistical tests. Data handling and analysis were performed
with R (v3.3.2).3. Results
From January 2007 to December 2015 a total of 9903 TAVI proce-
dures were recorded in the UK TAVI registry. Of the 2473 procedures
reported in 2015, the TF approach was the default vascular access
strategy (n = 2073, 83.8%). TA access was the next most common
(n = 163, 6.6%) followed by DA (n = 56, 2.3%) and SC (n = 43,
1.7%) routes.
In the primary analysis, there were 4033 TAVI procedures under-
taken from January 2013 up to July 2015. Of these 296 (7.3%) were per-
formed via the DA and SC access routes (192 [64.9%] and 104 [35.1%]
respectively) (see Online Supplement Fig. 1). After exclusion of cases
with missing information on mortality (short or long-term, 27 cases)
or other outcomes of interest (e.g. procedure duration, 14 cases), and
key covariates examined (e.g. age, 31 cases), the final analysis cohort in-
cluded 224 cases, 142 (63.4%) by DA and 82 (36.6%) by the SC route.
Follow-up ranged from 35 to 920 days (median follow-up amongst sur-
vivors 545 days).3.1. Patient and operative characteristics by vascular access route
The median age of patients was 81 (IQR 75–85) years and 54.9%
were male. DA access patients were marginally older. Significantly
more men were approached via the SC route (Table 1). The BMI distri-
bution was comparable. SC access was almost exclusively used for the
CoreValve (93.9%, 77 of 82) prosthesis, whereas the majority of DA
cases were for a Sapien valve (64.1%, 91 of 142).3.2. Unadjusted outcomes by vascular access route
Unadjusted 30-day mortality (post-TAVI) for the full cohort was
3.6%. In-hospital, 30-day and 1-year post-TAVI survival did not signifi-
cantly differ between groups, althoughmoreDAdeaths occurred overall
(Table 2). Long-term survival did not differ significantly between those
individuals exposed to SC versus DA access (Fig. 1).
Median procedure time was approximately 1 h longer for SC cases,
although SC cases were associated with earlier hospital discharge. A
higher proportion of SC patients required a permanent pacemaker
post TAVI though this was not statistically significant. The SC route
was associated with significantly more vascular access complications
and aortic regurgitation compared to the DA approach. Conversion to
full sternotomy, bailout valve in valve intervention, further valve inter-
vention and renal replacement therapy prior to discharge were rarely
required for either access route.3.3. Adjusted outcomes by vascular access route
The only significant predictor for long-term mortality after an ad-
justed Cox regression analysis was patient frailty as assessed by the
CSHA frailty score (hazard ratio [HR] 1.68, 95% confidence interval [CI
1.35, 2.09]; p b .01). The SC route was associated with a comparatively
lower all cause mortality risk (HR 0.71 [0.39, 1.29]; p = .258) although
this did not reach statistical significance.
Multivariable logistic regression showed that the two access routes
differed in certain key outcomes (Table 3). The SC caseswere associated
with a 38% longer mean procedure time yet resulted in a 29% shorter
mean length of hospital stay compared toDA cases. It isworthwhile not-
ing that the overall time in theatre reduced by 10% per calendar year.
The SC approach significantly reduced the odds of AKI (odds ratio [OR]
0.35, [0.12, 0.96]; p= .042). However, the SC route was also associated
with a doubling in the odds of aortic regurgitation (OR 2.08 [1.11, 3.91];
p = .023) and a nearly tenfold increase in vascular access site-related
complications (OR 9.75 [3.07, 30.93]; p b .01).
4. Discussion
The TF approach remains the default vascular access strategy for
TAVI. It is minimally invasive and allows performance of TAVI under
conscious sedation. However, roughly 10% of patients require an alter-
native access route [1,5].
The TA route is associated with more postoperative bleeding and a
highermortality than the TF approach [6,7]. This led to the development
of subclavian/axillary access, first described in 2008 [8]. A surgical cut
down is usually required, although a fully percutaneous method has
been more recently described [9] along with a move to perform appro-
priate cases under local anaesthetic.
The SC approach has been shown to have equivalent procedural suc-
cess and medium term results when compared with TF access using a
propensity-matched analysis of the Italian CoreValve Registry [10].
Equivalence in survival was also demonstrated against TA access in a
small multicentre study comprising 202 procedures, despite the TA ac-
cess causing significantlymore bleeding and a trend towards greater in-
hospital mortality [11]. Use of the SC approach, however, can be re-
stricted by anatomical features such as tortuosity or small vessel calibre.
Those with a pre-existing left internal mammary artery bypass graft
may also be exposed to the risk of ischemia during instrumentation
[12]. Moreover the relative lack of a muscular component to the wall
of the subclavian artery makes it more susceptible to dissection.
The DA approach was first reported in 2010. It offers direct delivery
within close proximity to the aortic annulus, a high level of control and
enhanced accuracy when positioning the prosthesis. A surgical incision
via an upper partial sternotomy or small right anterior thoracotomy
means invasiveness is relatively high. Risk is further exacerbated by
the need for general anaesthesia and mechanical ventilation [13,14]. A
suprasternal DA approach, performed under general anaesthesia but
avoiding sternotomy and thoracotomy, has also been reported [15].
DA access is a safe and feasible alternative to a TF strategy, when
the latter cannot be used [16–19]. DA access appears to have at least
equivalent or better rates of long- and short-term mortality, stroke
and bleeding when previously compared to the TA route [20–23].
Much of the observational data used to support these comparisons,
however, are limited to predominantly high surgical risk individuals.
Further validation in intermediate and lower risk cohorts are re-
quired in response to the inevitable broadening of the eligibility
criteria for TAVI.
There is a paucity of data directly comparing the SC andDA routes for
TAVI. In the absence of randomised controlled trial data, prospectively
collected observational data offer the best alternative for such a compar-
ison. In a prior analysis of the UK TAVI registry from January 2007 to De-
cember 2012, SC access demonstrated a similar 1-year survival rate to
TF. The TA and DA approaches were, however, found to have
Table 1
Patient and procedural characteristics for the primary analysis dataset (n= 224) accord-
ing to vascular access route for TAVI.
Variables
(Expressed as number and percentage









Mean (SD) age at admission (years) 78.3 (6.8) 80.0 (8.9) 0.139





Male 54 (65.9%) 69 (48.6%) 0.018
Mean (SD) BMI (kg/m2) 27.6 (5.4) 27.2 (6.7) 0.609





Diabetes 24 (29.3%) 37 (26.1%) 0.716
Current or ex-smoker 59 (72.0%) 85 (59.9%) 0.178
CSHA frailty score (range 1 to 7) 0.117
Very fit [1] 2 (2.4%) 2 (1.4%)
Well [2] 6 (7.3%) 13 (9.2%)
Well (with treated co-morbid disease)
[3]
28 (34.2%) 29 (20.4%)
Apparently vulnerable [4] 19 (23.2%) 33 (23.2%)
Mildly frail [5] 12 (14.6%) 30 (21.2%)
Moderately frail [6] 12 (14.6%) 33 (23.2%)
Severely frail [7] 3 (3.7%) 2 (1.4%)
History of pulmonary disease 0.223
No pulmonary disease 48 (58.6%) 94 (66.2%)
COPD/emphysema 27 (32.9%) 43 (30.3%)
Asthma 6 (7.3%) 3 (2.1%)
Other significant pulmonary disease 1 (1.2%) 2 (1.4%)
Previous cardiac surgery 0.067
None 59 (72.0%) 116 (81.7%)
Previous CABG 21 (25.6%) 19 (13.4%)
Other 2 (2.4%) 7 (4.9%)
Previous TAVI 1 (1.2%) 0 (0%)
Previous PCI 24 (29.3%) 25 (17.6%) 0.062
Previous MI 11 (13.4%) 34 (23.9%) 0.085
Balloon aortic valvuloplasty prior to TAVI b0.0001
Completed 64 (78.0%) 72 (50.7%)
Not performed 18 (22.0%) 70 (49.3%)
Extracardiac arteriopathy 47 (57.3%) 77 (54.2%) 0.757
Extensive calcification of ascending aorta
(grade 3 or 4)
16 (19.5%) 20 (14.1%) 0.381
Critical pre-operative status 3 (3.7%) 5 (3.5%) 1
Elective procedure 77 (93.9%) 122 (85.9%) 0.108
Left ventricular ejection fraction (LVEF)a 0.747
≥50% 41 (50.0%) 84 (59.1%)
(30–49%] 36 (43.9%) 43 (30.3%)
b30% 4 (4.9%) 15 (10.6%)
Procedural characteristics
Valve manufacturer 0.001
Boston Scientific 0 (0%) 10 (7.0%)
Edwards Lifesciences 1 (1.2%) 93 (65.5%)
Medtronic 80 (97.6%) 39 (27.5%)
Unknown 1 (1.2%) 0 (0%)
Valve model
CoreValve 77 (93.9%) 37 (26.1%)
CoreValve Evolut R 3 (3.7%) 0 (0%)
Engager 0 (0%) 1 (0.7%)
Lotus 0 (0%) 10 (7.1%)
SAPIEN 3 model 9000TFX 0 (0%) 9 (6.3%)
SAPIEN 3 model 9600TFX 1 (1.2%) 28 (19.7%)
SAPIEN XT model 9300TFX 0 (0%) 54 (38.0%)
Unknown 1 (1.2%) 3 (2.1%)
Year of procedure 0.706
2013 40 (48.8%) 77 (54.2%)
2014 32 (39.0%) 51 (35.9%)
2015 10 (12.2%) 14 (9.9%)
Key: BMI = body mass index; CABG= coronary artery bypass grafting; COPD = chronic
obstructive pulmonary disease; CSHA = Canadian Study on Health and Aging; IQR = in-
terquartile range;MI=myocardial infarction; PCI=percutaneous intervention coronary;
SD = standard deviation; TAVI = transcatheter aortic valve implantation.
a One unknown LVEF subclavian case.
Table 2
Clinical outcomes according to vascular access route from the UK TAVI registry.
Variables
(Expressed as number and percentage










In-hospital death 2 (2.4%) 7 (4.9%) 0.492
Death 30 days post TAVI 2 (2.4%) 6 (4.2%) 0.714
Death 1 year post TAVIa 8 (14.5%) 21 (21.9%) 0.344
Mean (SD) procedure time (mins) 193.5 (65.8) 138.4 (57.7) b0.0001





Mean (SD) length of stay (days)b 8.6 (9.5) 11.9 (10.8) 0.025
Median (IQR) length of stay (days)b 6 (4,8) 7 (6,14) 0.0002
Vascular access site related
complications
0.001
None 65 (79.3%) 137 (96.5%)
Minor 11 (13.4%) 3 (2.1%)
Major 6 (7.3%) 2 (1.4%)
Permanent pacemaker implantation
post procedure
20 (24.4%) 21 (14.8%) 0.107
Tamponade 0 (0%) 4 (2.8%) –
Further valve intervention prior to
discharge
0 (0%) 1 (0.7%) –
Bailout valve-in-valve
(non-emergency)
8 (9.8%) 1 (0.7%) 0.0006
Conversion to full sternotomy during
procedure
–
No 82 (100%) 140 (98.6%)
Yes (haemorrhage) 0 (0%) 1 (0.7%)
Yes (valve surgery) 0 (0%) 1 (0.7%)
Cerebrovascular accident 3 (3.7%) 3 (2.1%) 0.671
Bleeding 0.181
None 72 (87.8%) 117 (82.4%)
Minor 7 (8.5%) 15 (10.6%)
Major 3 (3.7%) 7 (4.9%)
Life threatening or disabling 0 (0%) 3 (2.1%)
Acute kidney injury 0.066
None 77 (93.9%) 116 (81.7%)
Stage 1 1 (1.2%) 11 (7.8%)
Stage 2 1 (1.2%) 9 (6.3%)
Stage 3 3 (3.7%) 6 (4.2%)
New renal replacement therapy prior to
discharge
1 (1.2%) 8 (5.6%) 0.16
Key: AKI = acute kidney injury; CVA = cerebrovascular accident; IQR = interquartile
range; SD = standard deviation.
a These figures correspond to a total of 151 patients performed before June 2014 to
ensure at least 1-year of follow-up.
b The length of stay analysis is based on the 215 patients alive at discharge.
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concluding that a SC strategy may represent the safest non-femoral ac-
cess route for TAVI [24].The present study directly compared the SC and DA approaches and
showed no survival advantage in favour of either strategy with respect
to in-hospital, 30-day and 1-year all cause mortality, although deaths
after the DA approach were numerically higher. The SC route was asso-
ciated with significantly more vascular access site complications and
aortic regurgitation. The latter may be explained by the fact almost all
SC procedureswere performed using theMedtronic CoreValve prosthe-
sis [25,26]. The numerically higher rate of permanent pacemaker im-
plantation after SC procedures are also likely to be associated with
CoreValve use [27]. Moreover, in a recent propensity-matched analysis
of the FRANCE-TAVI nationwide registry from January 2013 to Decem-
ber 2015, where patients treated with balloon-expandable prostheses
(n = 3910) were matched 1:1 with individuals treated with self-
expandable heart valves (n = 3910), use of the latter device was
found to cause significantlymore post-procedural paravalvular regurgi-
tation (p b .0001) and the need for permanent pacemaker implantation
(p b .0001) [28]. The true extent of our findings, therefore, require fur-
ther validation in a larger cohort as the respective confidence intervals
were relatively wide (Table 3).
SomeUK centres no longer useDA access as the recovery from a tho-
racotomy was found to be slow and patients were susceptible to chest
infections, post-operative renal dysfunction and had a longer hospital
stay. Further reports from the UK TAVI registry encompassing all
Fig. 1. Kaplan-Meier plot for survival after direct aortic versus subclavian access
transcatheter aortic valve implantation (TAVI) from the UK TAVI registry, January 2013
to July 2015.
Table 3
Effect of surgical subclavian versus direct aortic access on post TAVI complications and
procedural parameters obtained from multivariable logistic regression models.
Outcome Odds ratio 95% CI p-value
Procedure time 1.38a (1.23, 1.53) b0.001
Permanent pacemaker implantation 1.66 (0.83, 3.34) 0.154
Bleeding 0.54 (0.24, 1.25) 0.149
Acute kidney injury 0.35 (0.12, 0.96) 0.042
Aortic regurgitation 2.08 (1.11, 3.91) 0.023
Vascular access site complications 9.75 (3.07, 30.93) b0.01
Death 1 year post TAVI 0.59 (0.23, 1.57) 0.306
Outcome Mean ratioa 95% CI p-value
Procedure duration (minutes) 1.38 (1.23, 1.53) b0.001
Post-operative length of stay in hospital
(modelled on the 215 patients alive at discharge)
0.71 (0.58, 0.87) 0.001
Key: TAVI = transcatheter aortic valve implantation.
a This is the geometric mean ratio, as outcomes have been log-transformed to improve
normality.
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reports show an increasing trend towards use of SC over DA access
(2016, SC 94 vs. DA 65 procedures, 2017, SC 107 vs. DA 53 procedures)
[29,30]. Future studies will incorporate this data to further delineate
whether there is a survival advantage of SC over DA access.
4.1. Limitations
The current work suffers from all the limitations inherent to obser-
vational analyses of clinical registry data, thus the results should be
interpreted with caution. The data were prospectively collected by
each TAVI centre but there was no event adjudication committee for
this study. This exposes our analysis to potentially significant under-
reporting of complications, though mortality tracking avoided this
issue with regard to life status.
The number of SC and DA cases available for the analysis were rela-
tively small. This is a product of both the truncated period in which
there was validated life status available and that the predominant vas-
cular access strategy remains the TF route in the UK. Regrettably we
were unable to utilise data from 2016 and 2017 in our primary analysis
due to a lack of validated life status during this time period. The rela-
tively small size of our study cohort may have resulted in limited
power to detect significant associations between route and outcomes,
and to identify potentially important covariates.
There was a notable amount of missing data primarily related to in-
hospital outcomes. Multiple imputation, however, was not pursued
given the proportions involved was almost equitable between access
routes (21% SC vs. 25%DA). Furthermore the clinical nature of the cohort
examined allowed for thorough risk-adjustment in model building in
order to account for differences in patient profiles treated via either
strategy. Nevertheless, residual confounding cannot be excluded.
5. Conclusions
Surgical subclavian (or transaxillary) and direct aortic vascular ac-
cess routes are established, feasible and comparatively safe alternative
strategies to the default retrograde transfemoral access for TAVI. We
found no significant difference in short- or medium-term survivalbetween the two. However, in more recent years, there has been an in-
crease in the use of the transaxillary route (including percutaneous ap-
proaches performed under local anaesthetic) and a corresponding
decline in DA access. As with any operative technique, however, the de-
cision to select a specific approach will be determined by varying com-
binations of patient comorbidity, vascular anatomy, transcatheter heart
valve preference and the skill mix and expertise of the Heart Team.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.03.059.
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